Corporate Profile

Unum Therapeutics is a biopharmaceutical company focused on developing novel precision kinase inhibitors to treat a broad range of patients with unmet medical needs. Unum’s lead program, PLX9486, was designed to be a highly selective and potent KIT mutant inhibitor and exhibited promising early clinical activity and safety in  a Phase 1/2 trial in patients with advanced GIST.

By inhibiting primary KIT mutations as well as resistance and activation loop mutations, PLX9486 has the potential to fill an unmet need for patients living with GIST or Systemic Mastocytosis.

News Releases